Name: Kanteerbare in vivo herprogrammering van tumorcellen tot type 1 conventionele dendritische celachtige cellen (Video) | JoVE Journal
Uploaded: 2025-08-01T14:35:00.000+00:00
Duration: 10 min 4 s
Description: Leer hoe je muiskankercellen in vivo herprogrammeert tot type 1 dendritische celachtige cellen met behulp van transcriptiefactoren PU.1, IRF8 en BATF3. Deze methode versterkt anti-tumorimmuniteit door koude tumoren om te zetten in hete tumoren.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

<ol><li>Oliveira, G., Wu, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dynamics+and+specificities+of+T+cells+in+cancer+immunotherapy%5BTitle%5D)+AND+%22Nat+Rev+Cancer%22%5BJournal%5D)">Dynamics and specificities of T cells in cancer immunotherapy.</a> Nat Rev Cancer. 23 (5), 295-316 (2023).</li>
<li>Larkin, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Five-year+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma%5BTitle%5D)+AND+%22N+Engl+J+Med%22%5BJournal%5D)">Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.</a> N Engl J Med. 381 (16), 1535-1546 (2019).</li>
<li>Adams, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pembrolizumab+monotherapy+for+previously+untreated%2C+PD-L1-positive%2C+metastatic+triple-negative+breast+cancer%3A+cohort+B+of+the+phase+II+KEYNOTE-086+study%5BTitle%5D)+AND+%22Ann+Oncol%22%5BJournal%5D)">Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.</a> Ann Oncol. 30 (3), 405-411 (2019).</li>
<li>Patel, M. R., Falchook, G. S., Hamada, K., Makris, L., Bendell, J. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+phase+2+trial+of+trifluridine%2Ftipiracil+plus+nivolumab+in+patients+with+heavily+pretreated+microsatellite-stable+metastatic+colorectal+cancer%5BTitle%5D)+AND+%22Cancer+Med%22%5BJournal%5D)">A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.</a> Cancer Med. 10 (4), 1183-1190 (2021).</li>
<li>Reardon, D. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Randomized+phase+3+study+evaluating+the+efficacy+and+safety+of+nivolumab+vs+bevacizumab+in+patients+with+recurrent+glioblastoma%3A+CheckMate+143%5BTitle%5D)+AND+%22Neuro+Oncol%22%5BJournal%5D)">Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143.</a> Neuro Oncol. 19 (suppl_3), iii21-iii21 (2017).</li>
<li>Sharma, P., Hu-Lieskovan, S., Wargo, J. A., Ribas, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Primary%2C+adaptive%2C+and+acquired+resistance+to+cancer+immunotherapy%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Primary, adaptive, and acquired resistance to cancer immunotherapy.</a> Cell. 168 (4), 707-723 (2017).</li>
<li>Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., Sancho, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dendritic+cells+as+orchestrators+of+anticancer+immunity+and+immunotherapy%5BTitle%5D)+AND+%22Nat+Rev+Clin+Oncol%22%5BJournal%5D)">Dendritic cells as orchestrators of anticancer immunity and immunotherapy.</a> Nat Rev Clin Oncol. 21 (4), 257-277 (2024).</li>
<li>Heras-Murillo, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunotherapy+with+conventional+type-1+dendritic+cells+induces+immune+memory+and+limits+tumor+relapse%5BTitle%5D)+AND+%22Nat+Commun%22%5BJournal%5D)">Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse.</a> Nat Commun. 16 (1), 3369(2025).</li>
<li>Theisen, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((WDFY4+is+required+for+cross-presentation+in+response+to+viral+and+tumor+antigens%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">WDFY4 is required for cross-presentation in response to viral and tumor antigens.</a> Science. 362 (6415), 694-699 (2018).</li>
<li>Meiser, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+distinct+stimulatory+cDC1+subpopulation+amplifies+CD8%2B+T+cell+responses+in+tumors+for+protective+anti-cancer+immunity%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity.</a> Cancer Cell. 41 (8), 1498-1515.e10 (2023).</li>
<li>Spranger, S., Dai, D., Horton, B., Gajewski, T. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tumor-residing+Batf3+dendritic+cells+are+required+for+effector+T+cell+trafficking+and+adoptive+T+cell+therapy%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy.</a> Cancer Cell. 31 (5), 711-723.e4 (2017).</li>
<li>Hubert, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((IFN-III+is+selectively+produced+by+cDC1+and+predicts+good+clinical+outcome+in+breast+cancer%5BTitle%5D)+AND+%22Sci+Immunol%22%5BJournal%5D)">IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer.</a> Sci Immunol. 5 (46), eaav3942(2020).</li>
<li>Mahadevan, K. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Type+I+conventional+dendritic+cells+facilitate+immunotherapy+in+pancreatic+cancer%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer.</a> Science. 384 (6703), eadh4567(2024).</li>
<li>Ascic, E., Pereira, C. -F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Transcription+factor-mediated+reprogramming+to+antigen-presenting+cells%5BTitle%5D)+AND+%22Curr+Opin+Genet+Dev%22%5BJournal%5D)">Transcription factor-mediated reprogramming to antigen-presenting cells.</a> Curr Opin Genet Dev. 90, 102300(2025).</li>
<li>Silk, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cross-presentation+of+tumour+antigens+by+human+induced+pluripotent+stem+cell-derived+CD141%2B+XCR1%2B+dendritic+cells%5BTitle%5D)+AND+%22Gene+Ther%22%5BJournal%5D)">Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141+ XCR1+ dendritic cells.</a> Gene Ther. 19 (10), 1035-1040 (2012).</li>
<li>Nair, S., Archer, G. E., Tedder, T. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolation+and+generation+of+human+dendritic+cells%5BTitle%5D)+AND+%22Curr+Protoc+Immunol%22%5BJournal%5D)">Isolation and generation of human dendritic cells.</a> Curr Protoc Immunol. Chapter 7, 7.32.1-7.32.23 (2012).</li>
<li>Makino, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Generation+of+cDC-like+cells+from+human+induced+pluripotent+stem+cells+via+Notch+signaling%5BTitle%5D)+AND+%22J+Immunother+Cancer%22%5BJournal%5D)">Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.</a> J Immunother Cancer. 10 (1), e003827(2022).</li>
<li>Balan, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Large-scale+human+dendritic+cell+differentiation+revealing+Notch-dependent+lineage+bifurcation+and+heterogeneity%5BTitle%5D)+AND+%22Cell+Rep%22%5BJournal%5D)">Large-scale human dendritic cell differentiation revealing Notch-dependent lineage bifurcation and heterogeneity.</a> Cell Rep. 24 (7), 1902-1915.e6 (2018).</li>
<li>Kirkling, M. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Notch+signaling+facilitates+in+vitro+generation+of+cross-presenting+classical+dendritic+cells%5BTitle%5D)+AND+%22Cell+Rep%22%5BJournal%5D)">Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells.</a> Cell Rep. 23 (12), 3658-3672.e6 (2018).</li>
<li>Ascic, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+dendritic+cell+reprogramming+for+cancer+immunotherapy%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">In vivo dendritic cell reprogramming for cancer immunotherapy.</a> Science. 386 (6719), eadn9083(2024).</li>
<li>Rosa, F. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Direct+reprogramming+of+fibroblasts+into+antigen-presenting+dendritic+cells%5BTitle%5D)+AND+%22Sci+Immunol%22%5BJournal%5D)">Direct reprogramming of fibroblasts into antigen-presenting dendritic cells.</a> Sci Immunol. 3 (30), 1-16 (2018).</li>
<li>Rosa, F. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+transcriptional+profiling+informs+efficient+reprogramming+of+human+somatic+cells+to+cross-presenting+dendritic+cells%5BTitle%5D)+AND+%22Sci+Immunol%22%5BJournal%5D)">Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells.</a> Sci Immunol. 7 (69), eabg5539(2022).</li>
<li>Zimmermannova, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Restoring+tumor+immunogenicity+with+dendritic+cell+reprogramming%5BTitle%5D)+AND+%22Sci+Immunol%22%5BJournal%5D)">Restoring tumor immunogenicity with dendritic cell reprogramming.</a> Sci Immunol. 8 (85), eadd4817(2023).</li>
<li>Bouquet, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RapaCaspase-9-based+suicide+gene+applied+to+the+safety+of+IL-1RAP+CAR-T+cells%5BTitle%5D)+AND+%22Gene+Ther%22%5BJournal%5D)">RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.</a> Gene Ther. 30 (9), 706-713 (2023).</li>
<li>Huangfu, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+pluripotent+stem+cells+from+primary+human+fibroblasts+with+only+Oct4+and+Sox2%5BTitle%5D)+AND+%22Nat+Biotechnol%22%5BJournal%5D)">Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2.</a> Nat Biotechnol. 26 (11), 1269-1275 (2008).</li>
<li>Rojas, L. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Personalized+RNA+neoantigen+vaccines+stimulate+T+cells+in+pancreatic+cancer%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.</a> Nature. 618 (7963), 144-150 (2023).</li>
<li>Guan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemical+reprogramming+of+human+somatic+cells+to+pluripotent+stem+cells%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Chemical reprogramming of human somatic cells to pluripotent stem cells.</a> Nature. 605 (7909), 325-331 (2022).</li>
<li>Ferreira, A. G., Zimmermannova, O., Kurochkin, I., Ascic, E., Åkerström, F., Pereira, C. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reprogramming+cancer+cells+to+antigen-presenting+cells%5BTitle%5D)+AND+%22Bio+Protoc%22%5BJournal%5D)">Reprogramming cancer cells to antigen-presenting cells.</a> Bio Protoc. 13 (22), 1-25 (2023).</li>
<li>Cabrita, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tertiary+lymphoid+structures+improve+immunotherapy+and+survival+in+melanoma%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Tertiary lymphoid structures improve immunotherapy and survival in melanoma.</a> Nature. 577 (7791), 561-565 (2020).</li>
<li>Ng, K. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antibodies+against+endogenous+retroviruses+promote+lung+cancer+immunotherapy%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Antibodies against endogenous retroviruses promote lung cancer immunotherapy.</a> Nature. 616 (7957), 563-573 (2023).</li>
</ol>

<table><tbody><tr><td>0.45 &mu;m low-protein binding filter, 150 mL Bottle Top Vacuum Filter</td><td>Fisher scientific</td><td>15983297</td><td></td></tr><tr><td>2-Mercaptoethanol 50 mM</td><td>ThermoFisher Scientific</td><td>31350010</td><td></td></tr><tr><td>Anti-mouse CD45 Monoclonal Antibody (clone: 30-F11), Rat IgG2b, &kappa;</td><td>ThermoFisher Scientific</td><td>14-0451-82</td><td></td></tr><tr><td>B6.SJL-PtprcaPepcb/BoyCrl (CD45.1)</td><td>The Jackson Laboratory</td><td>002014</td><td></td></tr><tr><td>BD Micro-Fine U-100 Insulin Syringes (0.5 mL)</td><td>Fisher Scientific</td><td>11395751</td><td></td></tr><tr><td>C57BL/6J mice</td><td>The Jackson Laboratory</td><td>000664</td><td></td></tr><tr><td>Collagenase D</td><td>Sigma Aldrich</td><td>11088882001</td><td></td></tr><tr><td>Corning Falcon Cell Strainer For Use With 50ml Conical Tubes</td><td>Sigma Aldrich</td><td>CLS352340</td><td></td></tr><tr><td>Corning cover glasses 24 x 50 mm&nbsp;</td><td>Sigma Aldrich</td><td>CLS2975245</td><td></td></tr><tr><td>DAPI (4'6-diamidino-2-phenylindole, dihydrochloride)</td><td>ThermoFisher Scientific</td><td>D1306</td><td></td></tr><tr><td>DNase I</td><td>Sigma Aldrich</td><td>10104159001</td><td></td></tr><tr><td>eBioscience Fixable Viability Dye eFluor 450</td><td>Invitrogen</td><td>65-0863-14</td><td></td></tr><tr><td>eBioscience IHC Antigen Retrieval Solution - Low pH (10x)</td><td>ThermoFisher Scientific</td><td>00-4955-58</td><td></td></tr><tr><td>Fetal Bovine Serum (FBS)</td><td>ThermoFisher Scientific</td><td>A5256701</td><td></td></tr><tr><td>Fluoromount-G Mounting Medium</td><td>ThermoFisher Scientific</td><td>00-4958-02</td><td></td></tr><tr><td>GFP Antibody [Alexa Fluor 594]</td><td>Novus Biologicals</td><td>NB600-308AF594</td><td></td></tr><tr><td>Gibco DMEM/Nutrient Mixture F-12 (DMEM/F-12)</td><td>ThermoFisher Scientific</td><td>31331028</td><td></td></tr><tr><td>Gibco MEM Non-Essential Amino Acids Solution (100x)</td><td>ThermoFisher Scientific</td><td>11140035</td><td></td></tr><tr><td>Gibco Opti-MEM I</td><td>ThermoFisher Scientific</td><td>11058021</td><td></td></tr><tr><td>Gibco Roswell Park Memorial Institute (RPMI) 1640 Medium</td><td>ThermoFisher Scientific</td><td>52400025</td><td></td></tr><tr><td>Gibco Sodium Pyruvate (100 mM)</td><td>ThermoFisher Scientific</td><td>11360070</td><td></td></tr><tr><td>Gibco Trypan Blue Solution, 0.4%</td><td>ThermoFisher Scientific</td><td>15250061</td><td></td></tr><tr><td>GlutaMAX Supplement&nbsp;</td><td>ThermoFisher Scientific</td><td>35050061</td><td></td></tr><tr><td>Goat anti-rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Polyclonal, Alexa Fluor 488</td><td>ThermoFisher Scientific</td><td>A-11006</td><td></td></tr><tr><td>HEK 293T cells</td><td>ATTC</td><td>CRL-11268</td><td></td></tr><tr><td>Hexadimethrine bromide (Polybrene)</td><td>Sigma Aldrich</td><td>H9268</td><td></td></tr><tr><td>HyClone Dulbecco’s Modified Eagle Medium (DMEM) with high glucose</td><td>Cytiva</td><td>SH30243.01</td><td></td></tr><tr><td>HyClone Penicillin Streptomycin 100x Solution (Pen/Strep)</td><td>Cytiva</td><td>SV30010</td><td></td></tr><tr><td>HyClone Phosphate Buffered Saline solution (PBS)</td><td>Cytiva</td><td>SH30028.02</td><td></td></tr><tr><td>Ketaminol vet. Solution for injection 100 mg/mL</td><td>MSD Animal Health Sweden</td><td>QN01AX03</td><td></td></tr><tr><td>Microtome Blade - C35</td><td>pfm medical</td><td>207500005</td><td></td></tr><tr><td>Mouse anti-CD45.2 (104), Surface, APC, Monoclonal</td><td>Biolegend</td><td>109814</td><td></td></tr><tr><td>Mouse anti-MHCII (M5/114.15.2), Surface, PE-Cy7, Monoclonal</td><td>Biolegend</td><td>107630</td><td></td></tr><tr><td>Normal Goat Serum</td><td>Abcam</td><td>ab7481</td><td></td></tr><tr><td>Normal Rat Serum (sterile)</td><td>Abcam</td><td>ab7488</td><td></td></tr><tr><td>Open-Top Thinwall Polypropylene Tubes</td><td>Beckman Coulter Life Sciences</td><td>326823</td><td></td></tr><tr><td>Paraformaldehyde, 16% w/v aq. soln., methanol free</td><td>ThermoFisher Scientific</td><td>043368.9M</td><td></td></tr><tr><td>pFUW-tetO-Batf3, a monocistronic cassette encoding mouse Batf3</td><td>Addgene</td><td>139837</td><td></td></tr><tr><td>pFUW-tetO-Irf8, a monocistronic cassette encoding mouse Irf8</td><td>Addgene</td><td>139838</td><td></td></tr><tr><td>pFUW-tetO-Pu.1, a monocistronic cassette encoding mouse Pu.1</td><td>Addgene</td><td>139839</td><td></td></tr><tr><td>Plasmid pMD2.G</td><td>Addgene</td><td>12259</td><td></td></tr><tr><td>Plasmid psPAX2</td><td>Addgene</td><td>12260</td><td></td></tr><tr><td>Plasmid SFFV-eGFP (eGFP)</td><td>In house cloning</td><td>-</td><td></td></tr><tr><td>Plasmid SFFV-mCherry (mCherry)</td><td>In house cloning</td><td>-</td><td></td></tr><tr><td>Plasmid SFFV-PIB-eGFP,&nbsp; a polycistronic cassette encoding mouse PU.1, IRF8, and BATF3 (PIB)&nbsp;</td><td>In house cloning</td><td>-</td><td>Constructs and vectors used for reprogramming are available from Asgard Therapeutics under a material transfer agreement with the company</td></tr><tr><td>Polyethylenimine (PEI), Linear, MW 25000, Transfection Grade</td><td>Polysciences</td><td>23966</td><td></td></tr><tr><td>ReadyProbes Hydrophobic Barrier Pap Pen</td><td>ThermoFisher Scientific</td><td>R3777</td><td></td></tr><tr><td>Sodium Butyrate</td><td>Sigma Aldrich</td><td>303410</td><td></td></tr><tr><td>Sucrose</td><td>Sigma-Aldrich</td><td>S7903</td><td></td></tr><tr><td>SuperFrost Plus Adhesion Microscope Slides</td><td>Epredia</td><td>J1800AMNZ</td><td></td></tr><tr><td>Tissue-Tek O.C.T. Compound</td><td>Sakura Finetek</td><td>4583</td><td></td></tr><tr><td>TrypLE Express Enzyme (1x) no phenol red</td><td>ThermoFisher Scientific</td><td>12604021</td><td></td></tr><tr><td>TT Cryomold Intermediate, square (15 x 15 x 5 mm)</td><td>Sakura Finetek</td><td>4566</td><td></td></tr><tr><td>UltraPure 0.5 M EDTA, pH 8.0</td><td>Invitrogen</td><td>15575020</td><td></td></tr><tr><td>Xysol vet. Solution for injection 20 mg/mL</td><td>VM Pharma</td><td>QN05CM92</td><td></td></tr><tr><td>YUMM1.7 cells</td><td>Antineo</td><td></td><td></td></tr></tbody></table>

kanteerbare in vivo herprogrammering van tumorcellen tot type 1 conventionele dendritische celachtige cellen

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Kanteerbare in vivo herprogrammering van tumorcellen tot type 1 conventionele dendritische celachtige cellen

The efficacy of cancer immunotherapy relies on the recruitment and activation of cytotoxic T cell responses against solid tumors by type 1 conventional ...

tractable-vivo-reprogramming-tumor-cells-to-type-1-conventional

Research

JoVE Journal

Cancer Research

Kankeronderzoek

Genereren van T-lymfocyten van geïnduceerde pluripotente stamcellen (iPS) cellen geeft een alternatieve aanpak van het gebruik van embryonale stamcellen voor T-cel-gebaseerde immunotherapie. De werkwijze blijkt dat door een...

Geregisseerd Differentiatie van geïnduceerde pluripotente stamcellen naar T lymfocyten

This video demonstrates a technique for the ex vivo generation of tumor antigen-specific chimeric antigen receptor (CAR) T cells. Retroviral vectors carrying transgenic RNA are mixed with spleen cells in a medium supplemented with interleukin-2 to promote T-cell survival and proliferation. The mixture is then transferred to a plate coated with recombinant human fibronectin fragments and centrifuged to facilitate the fusion of the virus with the cell, allowing the RNA to integrate into the host...

An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells

De meest gebruikte methode voor het genereren van grote aantallen autologe dendritische cellen (DCs) voor gebruik bij tumor immunotherapie beschreven. De methode maakt gebruik van IL-4 en GM-CSF om DCs te onderscheiden van monocyten. De onrijpe DCs worden gestimuleerd om te rijpen en daarna beladen met antigenen voordat ze geïnjecteerd terug in de patiënt.

Voorbereiding van de Tumor antigenen opgeladen Mature dendritische cellen voor immunotherapie

Geëvalueerd in syngeneïsche immunocompetente gastheren, toonde het op kankerstamcel (CSC) gebaseerde dendritische cel (DC) vaccin een significant hogere antitumorimmuniteit aan dan traditionele DC-vaccins gepulseerd met heterogene bulktumorcellen.

Generatie van een nieuw dendritisch celvaccin met melanoom en plaveiselkankerstamcellen

We beschrijven een protocol om de radiale mobiliteit van niet-aderente immuuncellen in vitro te monitoren met behulp van een celsedimentatie manifold/slide apparaat. Celmigratie wordt gevolgd op monolagen van tumorcellen of op extracellulaire matrix-eiwitten. Onderzoek door licht- en fluorescentiemicroscopie maakt observatie van celmobiliteit en cytotoxische functionaliteit mogelijk.

Radial Mobiliteit en cytotoxische functie van retrovirale replicerende vector getransduceerde, niet-klevende Alloresponsive T-lymfocyten

Er bestaan verschillende zeldzame populaties van dendritische celsubpopulaties in lymfoïde organen en daarom zijn ze lastig te isoleren in voldoende aantallen en zuiverheid voor immunologische experimenten. Hier beschrijven we een methode met hoge efficiëntie en hoog rendement voor het isoleren van alle momenteel bekende belangrijke subpopulaties van dendritische cellen in de milt van muizen.

Een efficiënte en High Yield methode voor het isoleren van de muis dendritische cel subsets

Het doel van dit protocol is om het protocol te laten zien voor het herprogrammeren van in melanoom geïnfiltreerde tumorlymfocyten in geïnduceerde pluripotente stamcellen.

Generatie van geïnduceerde pluripotente stamcellen uit menselijke Melanoom-Tumor-infiltrerende lymfocyten

Dit artikel beschrijft een nieuwe methode voor het genereren van tumor antigeen-specifieke geïnduceerde pluripotente stamcel afkomstige Thymus emigants (iTE) door een driedimensionaal (3D) Thymus cultuur systeem. iET zijn een homogene deelverzameling van T-cellen die nauw verwant zijn aan naïeve T-cellen met de capaciteit voor proliferatie, Geheugenvorming en tumor onderdrukking.

Een driedimensionaal Thymic cultuur systeem voor het genereren van Murine geïnduceerde pluripotente stamcel afkomstige tumor antigen-specifieke Thymic emigranten

We beschrijven hier een flow Cytometry-based in vivo doden assay die het mogelijk maakt onderzoek van immunodominance in chemo T lymfocyten (CTL) Reacties op een model tumor antigeen. Wij bieden voorbeelden van hoe deze elegante assay kan worden gebruikt voor mechanistische studies en voor de effectiviteit van geneesmiddelen testen.

Maatwerk in vivo chemo tests om Immunodominance in tumor-specifieke CD8+ T Cell responsen te bestuderen

Dit artikel beschrijft een methode voor het genereren van functionele tumor antigen-specifieke geïnduceerde pluripotente stamcel-afgeleide CD8αβ+ enkele positieve T-cellen met behulp van OP9/dll1-co-cultuur systeem.

Met behulp van menselijke geïnduceerde pluripotente stamcellen voor het genereren van tumor-antigeen-specifieke T-cellen

Hier is een protocol voor de effectieve onderdrukking van replicatie van het hepatitis B-virus (HBV) in muizen door gebruik te maken van de adoptieve celoverdracht (ACT) van stamcel afkomstige virale antigeen (AG)-specifieke T-lymfocyten. Deze procedure kan worden aangepast voor mogelijke op ACT gebaseerde immunotherapie van HBV-infectie.

Stamcel afkomstige virale AG-specifieke T-lymfocyten onderdrukken HBV-replicatie bij muizen

Leer hoe je muiskankercellen in vivo herprogrammeert tot type 1 dendritische celachtige cellen met behulp van transcriptiefactoren PU.1, IRF8 en BATF3. Deze methode versterkt anti-tumorimmuniteit door koude tumoren om te zetten in hete tumoren.

Kanteerbare in vivo herprogrammering van tumorcellen tot type 1 conventionele dendritische celachtige cellen

Meer video's verkennen